Trial Profile

A phase 3 clinical trial to determine efficacy of umedaptanib pegol as an achondroplasia treatment

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 19 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Umedaptanib pegol (Primary)
Indications Achondroplasia
Focus Therapeutic Use

Most Recent Events

19 Nov 2025 New trial record
07 Oct 2025 According to a RIBOMIC media release, based on the successful completion of the phase 2 trial, company is planning a phase 3 clinical trial to further verify the efficacy of umedaptanib pegol as an ACH treatment.
07 Oct 2025 According to a RIBOMIC media release, phase 3 trial is scheduled to begin in the first quarter of fiscal year 2026 and conclude within fiscal year 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com